Panther Life Sciences Opens Next-Generation Microarray Patch (MAP) Platform to Pharma and Biotech Partners

Panther is inviting pharmaceutical and biotechnology partners to co-develop higher-efficacy, lower-toxicity, shelf-stable therapies using its MAP platform. We believe rethinking how treatments are ...
Business Wire

Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)

Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine delivered intradermally by Vaxxas’ high-density microarray ...
Business Wire

Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas’ High-Density Microarray Patch (HD-MAP) Delivery Technology

Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...